Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 15/20 | 0.68 |
| ▸ | DRD2 | P14416 | 4/20 | 0.57 |
| ▸ | DRD3 | P35462 | 3/20 | 0.57 |
| ▸ | HTR7 | P34969 | 6/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23261784 | 1.00 | HTR1A (0.68) | HTR1ADRD2DRD3HTR7SLC6A2 | |
| SCHEMBL23249314 | 1.00 | HTR1A (0.68) | HTR1ADRD2DRD3HTR7SLC6A2 | |
| SCHEMBL31635823 | 1.00 | HTR1A (0.68) | HTR1ADRD2DRD3HTR7SLC6A2 | |
| SCHEMBL31649590 | 0.85 | HTR1A (0.54) | HTR1ADRD2DRD3HTR7DRD4 | |
| SCHEMBL23249542 | 0.84 | HTR1A (0.80) | HTR1ADRD2DRD3DRD4 | |
| SCHEMBL23261643 | 0.84 | HTR1A (0.64) | HTR1ADRD2DRD3NISCH | |
| SCHEMBL6361652 | 0.81 | HTR1A (1.00) | HTR1ADRD2DRD3 | |
| SCHEMBL31649725 | 0.81 | HTR1A (0.57) | HTR1ADRD2DRD3HTR7NISCH | |
| SCHEMBL23261647 | 0.81 | HTR1A (0.60) | HTR1ADRD2DRD3NISCH | |
| SCHEMBL26266642 | 0.80 | HTR1A (0.58) | HTR1ADRD2DRD3NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250803-A1 | Combination of dopamine agonists and monoamine reuptake inhibitors | PFIZER INC | 2005-11-10 | — | — | US | claimed |
| WO-2005051488-A1 | COMBINATION OF DOPAMINE AGONISTS AND MONOAMINE REUPTAKE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-06-09 | — | — | WO | claimed |
| EP-0480939-B1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | UPJOHN CO (US) | 1995-01-25 | — | — | EP | claimed |
| US-5273975-A | Heterocyclic amines having central nervous system activity | THE UPJOHN COMPANY (US) | 1993-12-28 | — | — | US | claimed |
| WO-1990015058-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1990-12-13 | — | — | WO | claimed |
| WO-2025137639-A1 | MIXED SEROTONIN RECEPTOR BINDERS FOR TREATMENT OF PSYCHOTIC DISORDERS | DELIX THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20230295106-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | DELIX THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295106-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | DELIX THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295106-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | DELIX THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2021076572-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021076572-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20050250803-A1 | Combination of dopamine agonists and monoamine reuptake inhibitors | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| WO-2005051488-A1 | COMBINATION OF DOPAMINE AGONISTS AND MONOAMINE REUPTAKE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| US-5436240-A | Schizophrenia, Parkinson's disease, depression or hypotensive agents using tricyclic amines | THE UPJOHN COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| EP-0480939-B1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | UPJOHN CO (US) | 1995-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295106-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | GRIN1, GRIN2A, GRIN3B | HTR1A 746/4885DRD2 184/4885DRD3 375/4885 |
| US-20050250803-A1 | Combination of dopamine agonists and monoamine reuptake inhibitors | HTR5A, SLC6A3, SLC6A4 | HTR1A 5/4885DRD2 37/4885DRD3 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.